What revenue did Fusion Antibodies report for the year to 31 March 2026?

Fusion Antibodies reported unaudited revenue of £2.13m for the year to 31 March 2026, an increase of about 9% on FY2025.

Fusion Antibodies — TickStock

Timeline

Fusion Antibodies receives Canadian patent allowance for antibody library technology

07:25, 22 Jun 2026

Fusion Antibodies wins InnovateUK grant to humanise DR5 antibody

09:05, 15 Jun 2026

Fusion Antibodies shares dip after year-end trading statement

09:54, 5 May 2026 · Updated 14:35, 5 May

More in Healthcare

A laboratory technician is performing an analysis in a lab setting, wearing protective gear and using pipettes. The workspace features various laboratory equipment and samples, emphasizing a research environment.

Pharma

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Positive overall survival data from a China trial of risvutatug rezetecan marks the first Phase III success for any B7-H3-targeted antibody-drug conjugate, strengthening GSK's broader development programme.

Updated 14:01, 10 Jul 2026

Medtech & Diagnostics

Genedrive shares lifted after Parliament boost

Updated 13:53, 10 Jul 2026

Biotech

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

17:02, 9 Jul 2026

Healthcare Services

Toscafund gets four more weeks to move on Spire Healthcare bid

07:57, 9 Jul 2026

Biotech

Avacta settles £3.67m convertible bond payment in cash

07:53, 9 Jul 2026

Pharma

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

07:36, 9 Jul 2026

Medtech & Diagnostics

Smith and Nephew backs first German clinical consensus on single-use wound therapy

07:25, 9 Jul 2026

Pharma

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

13:39, 8 Jul 2026

Oil & Gas

Small Caps Today: Quadrise, Union Jack Oil, Galantas Gold, Itaconix, EDX Medical . . .

11:04, 8 Jul 2026

Biotech

Physiomics wins contracts across two service lines

10:21, 8 Jul 2026

Real Estate & REITs

Segro doubles new rent secured in first half as development pipeline hits record

09:55, 8 Jul 2026

Insight

What was Fusion Antibodies' year‑end cash balance?

Fusion Antibodies' year-end cash was £1.04 million.

Updated 22 Jun 2026

Insight

How much funding did Fusion Antibodies receive from the extended UKRI/InnovateUK Launchpad programme with Queen’s University Belfast?

The extended Launchpad programme provided total funding of more than £808,000, with up to £545,000 allocated to Fusion Antibodies.

Updated 22 Jun 2026

Insight

How much cash did Fusion Antibodies have at 31 March 2026?

Fusion Antibodies had £1.04m in cash at 31 March 2026.

Updated 15 Jun 2026

Identifiers

Ticker: FAB
ISIN: GB00BDQZGK16
LEI: 213800KBAYRC9VOQ9V39

Learn more on:

GLEIF

Timeline

Fusion Antibodies receives Canadian patent allowance for antibody library technology

Fusion Antibodies wins InnovateUK grant to humanise DR5 antibody

Fusion Antibodies shares dip after year-end trading statement

More in Healthcare

Hansoh Phase III win bolsters GSK's global case for Ris-Rez in lung cancer

Genedrive shares lifted after Parliament boost

Health & Bio Today: AstraZeneca ATTR-CM trial fails primary endpoint, Avacta, Spire Healthcare, Smith+Nephew

Toscafund gets four more weeks to move on Spire Healthcare bid

Avacta settles £3.67m convertible bond payment in cash

AstraZeneca and Ionis ATTR-CM trial fails primary endpoint

Smith and Nephew backs first German clinical consensus on single-use wound therapy

OKYO Pharma accelerates urcosimod into Phase 3 after FDA validates trial design

Small Caps Today: Quadrise, Union Jack Oil, Galantas Gold, Itaconix, EDX Medical . . .

Physiomics wins contracts across two service lines

Segro doubles new rent secured in first half as development pipeline hits record

Browse by Sector

Market reports

Energy & Resources

Financials

Technology

Healthcare

Industrials

Consumer